EANO guideline on the diagnosis and management of meningiomas
R Goldbrunner, P Stavrinou, MD Jenkinson… - Neuro …, 2021 - academic.oup.com
Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical trials
have been conducted to guide clinical decision making, resulting in variations of …
have been conducted to guide clinical decision making, resulting in variations of …
Signaling pathways in brain tumors and therapeutic interventions
S Li, C Wang, J Chen, Y Lan, W Zhang… - … and Targeted Therapy, 2023 - nature.com
Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …
Although there are few therapeutic options for brain tumors, enhanced biological …
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
P Sievers, T Hielscher, D Schrimpf, D Stichel… - Acta …, 2020 - Springer
Most high-grade meningiomas show a highly perturbed copy number profile and they are
enriched for TERT promoter mutations [6, 7, 11, 12]. In addition, homozygous focal deletions …
enriched for TERT promoter mutations [6, 7, 11, 12]. In addition, homozygous focal deletions …
Meningioma: a review of clinicopathological and molecular aspects
Meningiomas are the most the common primary brain tumors in adults, representing
approximately a third of all intracranial neoplasms. They classically are found to be more …
approximately a third of all intracranial neoplasms. They classically are found to be more …
Update from the 5th Edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base
LDR Thompson, JA Bishop - Head and Neck Pathology, 2022 - Springer
Abstract The World Health Organization Classification of Head and Neck Tumours recently
published the 5th edition. There are new entities, emerging entities, and significant updates …
published the 5th edition. There are new entities, emerging entities, and significant updates …
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic
Background Genomic studies of high-grade/progressive meningiomas have reported a
heterogeneous mutation spectrum, identifying few recurrently mutated genes. Most studies …
heterogeneous mutation spectrum, identifying few recurrently mutated genes. Most studies …
Molecular alterations in meningioma: prognostic and therapeutic perspectives
The mutational landscape of meningioma has expanded following the use of the new
genetic sequencing approaches. Novel mutations have been characterized and reveal their …
genetic sequencing approaches. Novel mutations have been characterized and reveal their …
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations
PK Brastianos, EL Twohy, ER Gerstner… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Patients with progressive or recurrent meningiomas have limited systemic
therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship …
therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship …
Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis
Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop
meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary …
meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary …
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Meningiomas are the most common primary intracranial tumors in adults and are increasing
in incidence due to the aging population and increased access to neuroimaging. While most …
in incidence due to the aging population and increased access to neuroimaging. While most …